AGM/EGMMay 15, 2026, 04:10 PM
Nurix Stockholders Elect Directors, Ratify Auditor, Approve Exec Comp
AI Summary
Nurix Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum was established with 80.98% of voting power present. Stockholders elected three Class III directors, Arthur T. Sands, Roger Dansey, and Paul M. Silva, each to serve a three-year term. Additionally, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 was ratified, and the compensation of the company's named executive officers was approved on a non-binding advisory basis.
Key Highlights
- Three Class III directors (Arthur T. Sands, Roger Dansey, Paul M. Silva) were elected for three-year terms.
- Arthur T. Sands received 63,592,948 votes for election.
- Roger Dansey received 79,607,489 votes for election.
- Paul M. Silva received 59,298,612 votes for election.
- Stockholders ratified PricewaterhouseCoopers LLP as the independent auditor with 83,555,977 votes for.
- Non-binding advisory approval of executive compensation passed with 72,458,920 votes for.
- A quorum was met with 83,747,013 shares (80.98% of voting power) present at the meeting.
Price Impact
More from NRIX